[go: up one dir, main page]

ES2528363T3 - Tratamiento para el cáncer - Google Patents

Tratamiento para el cáncer Download PDF

Info

Publication number
ES2528363T3
ES2528363T3 ES05813351.3T ES05813351T ES2528363T3 ES 2528363 T3 ES2528363 T3 ES 2528363T3 ES 05813351 T ES05813351 T ES 05813351T ES 2528363 T3 ES2528363 T3 ES 2528363T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
alkenylalkyl
cycloalkenylalkyl
cycloalkylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05813351.3T
Other languages
English (en)
Inventor
David L. Morris
Mohammad Hossein Pourgholami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pitney Pharmaceuticals Pty Ltd
Original Assignee
Pitney Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004906983A external-priority patent/AU2004906983A0/en
Application filed by Pitney Pharmaceuticals Pty Ltd filed Critical Pitney Pharmaceuticals Pty Ltd
Application granted granted Critical
Publication of ES2528363T3 publication Critical patent/ES2528363T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Al menos un taxoide en una cantidad efectiva y al menos un compuesto carbamato de benzimidazol de fórmula I:**Fórmula** en la que R1 se selecciona de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, -SR7, -SOR8, -SO2R9, -SCN, B'(CH2)nBR10, -C(O)-R11 o -OR12, COOR13, -NO2, NR13aCOOR13b, isotiocianato o -CN donde R7 a R13b se seleccionan cada uno independientemente de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, B y B' se seleccionan independientemente de O, S, S(O) o SO2 y n es de 1 a 4; R2 se selecciona de H o alquilo sustituido o no sustituido; R3 se selecciona de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, anillo heterocíclico de 5 o 6 miembros, cuyo(s) heteroátomo(s) se selecciona(n) de uno o más de O, S y/o N, -SR14, -OR15, -SOR16, -SO2R17, -SCN, -C(O)-R18, - OR19, NR20COOR21, en donde R15 a R21 cada uno se selecciona independientemente de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo o arilalquilo; en una cantidad efectiva para su uso en el tratamiento de un tumor de ovario en un sujeto.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES05813351.3T 2004-12-06 2005-12-06 Tratamiento para el cáncer Active ES2528363T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004906983A AU2004906983A0 (en) 2004-12-06 Treatment for cancer
AU2004906983 2004-12-06
PCT/AU2005/001839 WO2006060853A1 (en) 2004-12-06 2005-12-06 Treatment for cancer

Publications (1)

Publication Number Publication Date
ES2528363T3 true ES2528363T3 (es) 2015-02-09

Family

ID=36577596

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05813351.3T Active ES2528363T3 (es) 2004-12-06 2005-12-06 Tratamiento para el cáncer

Country Status (9)

Country Link
US (2) US20090286838A1 (es)
EP (1) EP1830847B1 (es)
JP (1) JP2008522984A (es)
KR (1) KR101287917B1 (es)
CN (1) CN101111248A (es)
CA (1) CA2589828C (es)
ES (1) ES2528363T3 (es)
PT (1) PT1830847E (es)
WO (1) WO2006060853A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
KR20090046142A (ko) 2007-11-05 2009-05-11 삼성전자주식회사 입력 필체 자동 변환 시스템 및 방법
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
WO2010135534A2 (en) * 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
US20120202840A1 (en) * 2009-10-09 2012-08-09 University Health Network Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
NZ729555A (en) 2012-08-06 2017-08-25 Pitney Pharmaceuticals Pty Ltd Compounds for the treatment of mtor pathway related diseases
CN103054858A (zh) * 2013-01-21 2013-04-24 杭州雷索药业有限公司 奥苯达唑在制备抗血管生成类药物中的应用
AU2014344789B2 (en) * 2013-11-01 2019-10-03 Pitney Pharmaceuticals Pty Limited Pharmaceutical combinations for the treatment of cancer
US20210015757A1 (en) * 2019-07-18 2021-01-21 Nano Targeting & Therapy Biopharma Inc Drug delivery by pore-modified mesoporous silica nanoparticles
CN111388469B (zh) * 2019-10-21 2021-11-02 温州医科大学 一种芬苯达唑在制备抗肿瘤药物中的应用
JP7568309B2 (ja) * 2019-10-21 2024-10-16 アキュラ ナノメディスン コーポレーション 癌を処置する方法
KR102516896B1 (ko) * 2020-10-19 2023-04-03 고려대학교 산학협력단 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
CN113648308A (zh) * 2021-09-14 2021-11-16 东莞市人民医院 奥芬达唑作为抗卵巢癌药物的应用
FR3151700A1 (fr) 2023-07-28 2025-01-31 Soitec Procédé de fabrication d’un substrat de diamant ou d’un matériau III-V pour applications en microélectronique
CN118908896A (zh) * 2024-09-02 2024-11-08 广东海洋大学 4-（1H-苯并[d]咪唑-2-基）-N，N-双（2-氯乙基）苯胺衍生物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
WO2001083457A2 (en) * 2000-04-28 2001-11-08 The Procter & Gamble Company Benzimidazole-2-carbamates and their use in cancer treatment
WO2002067932A1 (en) * 2001-01-11 2002-09-06 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
EP1379242B1 (en) * 2001-03-26 2012-08-15 Newsouth Innovations Pty Limited Method for treatment of cancer and compositions for use therein
ES2295695T3 (es) * 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.

Also Published As

Publication number Publication date
EP1830847A1 (en) 2007-09-12
PT1830847E (pt) 2015-02-05
CN101111248A (zh) 2008-01-23
JP2008522984A (ja) 2008-07-03
KR20070112113A (ko) 2007-11-22
CA2589828A1 (en) 2006-06-15
US20120214856A1 (en) 2012-08-23
EP1830847B1 (en) 2014-11-19
US20090286838A1 (en) 2009-11-19
KR101287917B1 (ko) 2013-07-23
EP1830847A4 (en) 2012-09-12
CA2589828C (en) 2014-07-08
US8835478B2 (en) 2014-09-16
WO2006060853A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
ES2528363T3 (es) Tratamiento para el cáncer
PE20241625A1 (es) Combinaciones farmaceuticas de inhibidores de sos1 para tratar o prevenir cancer
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
RU2485104C2 (ru) Новые производные 1,2-дигидрохинолина, обладающие активностью связывания глюкокортикоидного рецептора
RU2008144805A (ru) Применение биарилкарбоксамидов в лечении заболеваний, связанных с hedgehog-путем
AR054799A1 (es) Derivados de oxindol
RU2001121138A (ru) Ингибиторы тромбина
BR112022001931A2 (pt) Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer
RU2011108563A (ru) Способы лечения талассемии
KR930005985A (ko) Hiv 역전사효소의 억제제
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
RU2004117545A (ru) Аминопиримидины и пиридины
CL2009000323A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
PE20070135A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
RU2006112593A (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk
JP2006508030A5 (es)
EA200401613A1 (ru) Лекарственное средство для лечения рака
PE20010932A1 (es) N-[5 [[[5-alquil-2-oxazolil] metil] tio]-2-tiazolil]]-carboxamida inhibidores de cinasas dependientes de ciclina
PE20020585A1 (es) Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona
AR048361A1 (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
ATE270103T1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
AR086367A1 (es) Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka
EA200800924A1 (ru) Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
PE20110294A1 (es) Compuestos heterociclicos como inhibidores de enzimas de senal especifica